Substance / Medication

Unoprostone isopropyl

Overview

Active Ingredient
isopropyl unoprostone
RxNorm CUI
135313

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Research Evidence

Published studies and systematic reviews

Sort:
Therapeutic efficacy of topical unoprostone isopropyl in retinitis pigmentosa.
Akiyama Masato, Ikeda Yasuhiro, Yoshida Noriko et al. · Acta Ophthalmol · 2014
PMID: 24868583RCT
Sorption of unoprostone isopropyl to packaging materials.
Wong Michelle, Marion Robert, Reed Ken et al. · Int J Pharm · 2006
PMID: 16288842Observational
Unoprostone isopropyl and metabolite M1 activate BK channels and prevent ET-1-induced [Ca²⁺]i increases in human trabecular meshwork and smooth muscle.
Cuppoletti John, Malinowska Danuta H, Tewari Kirti P et al. · Invest Ophthalmol Vis Sci · 2012
PMID: 22786902Other
Vasodilatory mechanisms of unoprostone isopropyl in isolated porcine retinal arterioles.
Tanano Ichiro, Nagaoka Taiji, Ono Shinji et al. · Mol Vis · 2015
PMID: 26120274PreclinicalFull text (PMC)
The effect of unoprostone isopropyl on Ca2+ release-activated Ca2+ currents in cultured monkey trabecular meshwork cells and ciliary muscle cells.
Shimura Masahiko, Yasuda Kanako, Nakzawa Toru et al. · J Ocul Pharmacol Ther · 2006
PMID: 16910861Preclinical
Vasodilatory mechanism of unoprostone isopropyl on isolated rabbit ciliary artery.
Yoshitomi Takeshi, Yamaji Kazutsuna, Ishikawa Hitoshi et al. · Curr Eye Res · 2004
PMID: 14977518Preclinical
Low incidence of iris pigmentation and eyelash changes in 2 randomized clinical trials with unoprostone isopropyl 0.15%.
McCarey Bernard E, Kapik Barry M, Kane Frances E et al. · Ophthalmology · 2004
PMID: 15288975Trial

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Unoprostone isopropyl (substance)
SNOMED CT
410844009
UMLS CUI
C0527038
RxNorm CUI
135313

Clinical Data

This intervention maps to 3 entities in the Healos knowledge graph.

3
Conditions
0
Biomarkers
0
Specialists
0
Symptoms

Data is sourced from SNOMED CT, UMLS, and the Healos clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.